Picture of UK Houses of Parliament

Leading national thinking on politics, government & public policy through Open Access research

Strathprints makes available scholarly Open Access content by researchers in the School of Government & Public Policy, based within the Faculty of Humanities & Social Sciences.

Research here is 1st in Scotland for research intensity and spans a wide range of domains. The Department of Politics demonstrates expertise in understanding parties, elections and public opinion, with additional emphases on political economy, institutions and international relations. This international angle is reflected in the European Policies Research Centre (EPRC) which conducts comparative research on public policy. Meanwhile, the Centre for Energy Policy provides independent expertise on energy, working across multidisciplinary groups to shape policy for a low carbon economy.

Explore the Open Access research of the School of Government & Public Policy. Or explore all of Strathclyde's Open Access research...

Transferrin-bearing dendrimers for cancer therapy : an update

Somani, Sukrut and Dufes, Christine (2015) Transferrin-bearing dendrimers for cancer therapy : an update. Nanomedicine, 10 (14). pp. 2125-2127. ISSN 1743-5889

Text (Somani-Dufes-N2015-transferrin-bearing-dendrimers-cancer-therapy)
Accepted Author Manuscript

Download (129kB)| Preview


    Recent advances in multi-disciplinary research have resulted in the emergence of an increasing number of promising therapeutic strategies against cancer. However, the intravenous administration of these drugs is often limited by their inability to specifically reach the tumors, thus resulting in damaging secondary effects on healthy tissues. In order to remediate to this problem, a wide range of delivery systems have been investigated, aiming to specifically target the cancer cells and deliver their cargo to the pathological site. Among them, transferrin-bearing dendrimers are emerging as highly promising non-viral vectors for efficiently delivering drugs and nucleic acids to the cancer cells. The focus of this editorial is to provide an update on the therapeutic advances being made so far when using these targeted delivery systems.